Novel inhibitors of human immunodeficiency virus type 2 infectivity

Journal of General Virology

Volumn 95, Issue , 2014, Pages 2778-2783

  Beach, Lauren B ^a,b   Rawson, Jonathan M ^a,b   Kim, Baek ^c   Patterson, Steven E ^a,d   Mansky, Louis M ^a,b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZACITIDINE; CLOFARABINE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; GEMCITABINE; HIV 2 REVERSE TRANSCRIPTASE; NEVIRAPINE; NUCLEOTIDYLTRANSFERASE; RALTEGRAVIR; RESVERATROL; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG POTENCY; EC50; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MUTAGENESIS; NONHUMAN; REVERSE TRANSCRIPTION; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN; PHYSIOLOGY;

ANTIVIRAL AGENTS; CELL LINE; HIV-2; HUMANS; MUTAGENESIS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 84907436129     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.069864-0     Document Type: Article

References (43)

1. Ahn, J., Hao, C., Yan, J., DeLucia, M., Mehrens, J., Wang, C., Gronenborn, A. M. & Skowronski, J. (2012). HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J Biol Chem 287, 12550-12558.
2. Amie, S. M., Daly, M. B., Noble, E., Schinazi, R. F., Bambara, R. A. & Kim, B. (2013). Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem 288, 20683-20691.
3. Andreatta, K., Miller, M. D. & White, K. L. (2013). HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr 62, 367-374.
4. Baldauf, H. M., Pan, X., Erikson, E., Schmidt, S., Daddacha, W., Burggraf, M., Schenkova, K., Ambiel, I., Wabnitz, G. & other authors (2012). SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat Med 18, 1682-1687.
5. Balzarini, J. (2004). Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4, 921-944.
6. Biron, F., Lucht, F., Peyramond, D., Fresard, A., Vallet, T., Nugier, F., Grange, J., Malley, S., Hamedi-Sangsari, F. & Vila, J. (1995). Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 10, 36-40.
7. Bouré e, P., Lamour, P., Bisaro, F. & Didier, E. (1995). [Study of an HIV positive, tropical origin population in a refugee centre in France]. Bull Soc Pathol Exot 88, 24-28 (in French).
8. Boyer, P. L., Sarafianos, S. G., Clark, P. K., Arnold, E. & Hughes, S. H. (2006). Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2, e10.
9. Boyer, P. L., Clark, P. K. & Hughes, S. H. (2012). HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol 86, 5885-5894.
10. Campbell-Yesufu, O. T. & Gandhi, R. T. (2011). Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 52, 780-787.
11. Clavel, F., Guyader, M., Gué tard, D., Sallé, M., Montagnier, L. & Alizon, M. (1986). Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324, 691-695.
12. Clouser, C. L., Patterson, S. E. & Mansky, L. M. (2010). Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 84, 9301-9309.
13. Clouser, C. L., Holtz, C. M., Mullett, M., Crankshaw, D. L., Briggs, J. E., Chauhan, J., VanHoutan, I. M., Patterson, S. E. & Mansky, L. M. (2011). Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS ONE 6, e15840.
14. Clouser, C. L., Chauhan, J., Bess, M. A., van Oploo, J. L., Zhou, D., Dimick-Gray, S., Mansky, L. M. & Patterson, S. E. (2012a). Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett 22, 6642-6646.
15. Clouser, C. L., Holtz, C. M., Mullett, M., Crankshaw, D. L., Briggs, J. E., O’Sullivan, M. G., Patterson, S. E. & Mansky, L. M. (2012b). Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrob Agents Chemother 56, 1942-1948.
16. Costarelli, S., Torti, C., Rodella, A., Baldanti, F., Paolucci, S., Lapadula, G., Manca, N., Quiros-Roldan, E., Izzo, I. & Carosi, G. (2008). Screening and management of HIV-2-infected individuals in northern Italy. AIDS Patient Care STDS 22, 489-494.
17. Daelemans, D., Pauwels, R., De Clercq, E. & Pannecouque, C. (2011). A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc 6, 925-933.
18. Dapp, M. J., Clouser, C. L., Patterson, S. & Mansky, L. M. (2009). 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol 83, 11950-11958.
19. Dapp, M. J., Patterson, S. E. & Mansky, L. M. (2013). Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol 21, 56-62.
20. Diamond, T. L., Roshal, M., Jamburuthugoda, V. K., Reynolds, H. M., Merriam, A. R., Lee, K. Y., Balakrishnan, M., Bambara, R. A., Planelles, V. & other authors (2004). Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem 279, 51545-51553.
21. Frank, I., Bosch, R. J., Fiscus, S., Valentine, F., Flexner, C., Segal, Y., Ruan, P., Gulick, R., Wood, K. & other authors (2004). Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 20, 916-926.
22. Gottlieb, G. S., Badiane, N. M., Hawes, S. E., Fortes, L., Toure, M., Ndour, C. T., Starling, A. K., Traore, F., Sall, F. & other authors (2009). Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 48, 476-483.
23. Harris, K. S., Brabant, W., Styrchak, S., Gall, A. & Daifuku, R. (2005). KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 67, 1-9.
24. Kim, B., Nguyen, L. A., Daddacha, W. & Hollenbaugh, J. A. (2012). Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J Biol Chem 287, 21570-21574.
25. Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E. C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M. & other authors (2012). SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 13, 223-228.
26. Lori, F., Malykh, A. G., Foli, A., Maserati, R., De Antoni, A., Minoli, L., Padrini, D., Degli Antoni, A. M., Barchi, E. & other authors (1997). Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 13, 1403-1409.
27. MacNeil, A., Sarr, A. D., Sankalé, J. L., Meloni, S. T., Mboup, S. & Kanki, P. (2007). Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 81, 5325-5330.
28. Mené ndez-Arias, L. & Alvarez, M. (2014). Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 102, 70-86.
29. Mullins, J. I., Heath, L., Hughes, J. P., Kicha, J., Styrchak, S., Wong, K. G., Rao, U., Hansen, A., Harris, K. S. & other authors (2011). Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS ONE 6, e15135.
30. Nguyen, L. A., Kim, D. H., Daly, M. B., Allan, K. C. & Kim, B. (2014). Host SAMHD1 protein promotes HIV-1 recombination in macrophages. J Biol Chem 289, 2489-2496.
31. Ntemgwa, M. L., d’Aquin Toni, T., Brenner, B. G., Camacho, R. J. & Wainberg, M. A. (2009). Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 53, 3611-3619.
32. Post, K., Guo, J., Howard, K. J., Powell, M. D., Miller, J. T., Hizi, A., Le Grice, S. F. & Levin, J. G. (2003). Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription. J Virol 77, 7623-7634.
33. Rawson, J. M., Heineman, R. H., Beach, L. B., Martin, J. L., Schnettler, E. K., Dapp, M. J., Patterson, S. E. & Mansky, L. M. (2013). 5, 6-Dihydro-5-aza-29-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem 21, 7222-7228.
34. Rey, M. A., Krust, B., Laurent, A. G., Gué tard, D., Montagnier, L. & Hovanessian, A. G. (1989). Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology 173, 258-267.
35. Rodé s, B., Holguín, A., Soriano, V., Dourana, M., Mansinho, K., Antunes, F. & González-Lahoz, J. (2000). Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 38, 1370-1374.
36. Roquebert, B., Damond, F., Collin, G., Matheron, S., Peytavin, G., Bé nard, A., Campa, P., Cheˆ ne, G., Brun-Vé zinet, F. & other authors (2008). HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62, 914-920.
37. Smith, R. A., Gottlieb, G. S., Anderson, D. J., Pyrak, C. L. & Preston, B. D. (2008). Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 52, 329-332.
38. Smith, R. A., Anderson, D. J., Pyrak, C. L., Preston, B. D. & Gottlieb, G. S. (2009). Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 199, 1323-1326.
39. Smith, R. A., Raugi, D. N., Kiviat, N. B., Hawes, S. E., Mullins, J. I., Sow, P. S., Gottlieb, G. S. & University of Washington-Dakar HIV-2 Study Group (2011). Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 25, 2235-2241.
40. Soares, R. S., Tendeiro, R., Foxall, R. B., Baptista, A. P., Cavaleiro, R., Gomes, P., Camacho, R., Valadas, E., Doroana, M. & other authors (2011). Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol 85, 2429-2438.
41. St Gelais, C., de Silva, S., Amie, S. M., Coleman, C. M., Hoy, H., Hollenbaugh, J. A., Kim, B. & Wu, L. (2012). SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology 9, 105.
42. van der Ende, M. E., Kroes, A. C., Buitenwerf, J. & van der Poel, C. L. (1990). [Aids caused by HIV-2 in The Netherlands]. Ned Tijdschr Geneeskd 134, 495-497 (in Dutch).
43. Witvrouw, M., Pannecouque, C., Switzer, W. M., Folks, T. M., De Clercq, E. & Heneine, W. (2004). Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9, 57-65.